Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The share price is basically moving sideways with slight bent to the upside.
That would be too obvious unless for good cause. There is no good cause. Thus, a subtle approach.
I buy what Circa says. What is said is realistic. Anyone that believes that Big Pharma is not interested in going to great lengths to protect blockbuster drugs, whether they work or not, bringing in billions of dollars is not being realistic. If anyone sponsors a conference conference -- any conference -- they expect and do have an influence on what is presented at the conference. I know that when I sponsored a conference (in another field) I had an influence on what was presented as did every other sponsor. In the world of business -- especially big business -- there's many business employees whose lives are dependent on salaries, bonuses, and "business reputations" from their promotions of their major products. Gaining exclusivity, eliminating competition, and extending and protecting market share of billion dollar sales of any drug product is first and foremost for Big Pharma to keep meeting earnings expectations of shareholders and awarding employees.
I agree. My shares of AVXL are in a non-margin account. I have been solicited to participate. Personally, I have declined. I cannot bring myself to do that. I am a bit up in age, have friends that have succumbed to Alzheimer's, Parkinson's, etc.
However, I do not condemn those that do. Just remember though that if it sounds too good to be true there has to be a catch as IP MAN points out. Fidelity and others desire to get you to commit to their advantage -- not yours -- as you may rudely discover.
Think before you jump! Read the fine print. I bet it includes an agreement to arbitration, which is one sided in their favor. They always do that. Arbitration agreements -- clauses these people use are always in their favor -- not yours. If there is a problem, you will then understand what I am saying. Otherwise, I wish you good luck!
CBD: I like what you said. Good perspective!
As I understand it (0rveko is much more knowledgable than me) a new drug once approved may be entitled to limited exclusivity of something like 4-5 years regardless of a patent. However, Orveko indicated that there is an old patent application Anavex has on file for 2-73 alone as I recall. That patent has been dormant for a number of years. Anavex certainly would not want to abandon that patent application assuming it still exists.
Orveko has pointed out that A2-73 is currently protected by one patent related to its use as a combination therapy for the treatment of melanoma, but that does not protect 2-73 as a mono-therapy.
Of course, there may be quite a few other patent applications as someone on this board pointed out. I believe they were referring to combination patents.
Plus, there is something like a 7 year exclusivity for Orphan drug approval -- approval of 2-73 for Rhett Syndrome, etc.
Lastly, Anavex has good patent attorney representation. Therefore, I believe they are diligently pursuing all sorts of patent protection including protection for A3-71 -- another Anavex drug candidate.
Right, it's not a random event. It is significant. It was a deliberate purchase of a larger than normal number of shares. It was not done for the purpose of simply throwing several hundred thousands of dollars away.
Thank you. That is good to know.
My response to after hours trading: Whomever is doing this can go take a flying leap, assuming this was done for some nefarious purpose, -- a few trades of 200 to 400 shares each versus over 3.6 million shares traded during the normal trading hours. In any event, whether nefarious or not, it is extremely small volume -- yawn. Now, if they decide to sell millions of shares after hours for $4.25 I might pay a little more attention, but that would be pretty stupid in my opinion.
Am I reading that right? 1,764,762 trade @ $4.55 right at the closing bell.
“Be vigilant; guard your mind against negative thoughts.” Budda
I bought some St. Claire’s Organic Peppermints today. The inscription inside the box said that.
Excellent. Thank you.
Competition for Anavex by TauRx? The question I have is: How much of a competitor? Thus, I put all of the below together.
One theory of how AVXL 2-73 works is that it stops or limits nitration and oxidative stress. There is evidence that suggests that oxidative damage to proteins and other macromolecules is a feature of the pathology of Alzheimer’s disease. See: Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease - The Journal of Neuroscience www.jneurosci.org › content.
''Increasing evidence suggests that oxidative damage to proteins and other macromolecules is a salient feature of the pathology of Alzheimer’s disease. Establishing the source of oxidants is key to understanding what role they play in the pathogenesis of Alzheimer’s disease, and one way to examine this issue is to determine which oxidants are involved in damage.
In this study, we examine whether peroxynitrite, a powerful oxidant produced from the reaction of superoxide with nitric oxide, is involved in Alzheimer’s disease. Peroxynitrite is a source of hydroxyl radical-like reactivity, and it directly oxidizes proteins and other macromolecules with resultant carbonyl formation from side-chain and peptide-bond cleavage. Although carbonyl formation is a major oxidative modification induced by peroxynitrite, nitration of tyrosine residues is an indicator of peroxynitrite involvement. In brain tissue from cases of Alzheimer’s disease, we found increased protein nitration in neurons, including but certainly not restricted to those containing neurofibrillary tangles (NFTs). Conversely, nitrotyrosine was undetectable in the cerebral cortex of age-matched control brains. This distribution is essentially identical to that of free carbonyls.
These findings provide strong evidence that peroxynitrite is involved in oxidative damage of Alzheimer’s disease. Moreover, the widespread occurrence of nitrotyrosine in neurons suggests that oxidative damage is not restricted to long-lived polymers such as NFTs, but instead reflects a generalized oxidative stress that is important in disease pathogenesis."
See also NEW YORK, NY – February 25, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) is encouraged by the findings of a research report in the current issue of peer-reviewed scientific journal Frontiers in Cellular Neuroscience. Among its conclusions, the report reveals that ANAVEX 2-73 prevents mitochondrial dysfunction and blocks resulting oxidative stress and apoptosis (cell death) in a nontransgenic mouse model of Alzheimer’s disease (AD). Mitochondrial damages have been consistently reported as an early cause of AD and appear before amyloid-beta plaques and memory decline in Alzheimer’s patients and transgenic mice. Thus, by preserving mitochondrial functionality and reducing other key AD hallmarks, ANAVEX 2-73 has the potential to prevent, stop, slow or reverse the disease, in addition to treating its symptoms.
TauRx is a competitor of Anavex. TauRx may prevent tau aggregation, and as pointed out by Ipulator: "Many of TRx023's supposed beneficial effects, including neuroprotection via mitochondrial antioxidant properties...." makes for competition for Anavex.
Orveko had this to say about TauRx:
''orveko_inc Sunday, 07/05/15 01:57:49 PM
Re: Rwingsguy post# 5618
Post # of 65440
TauRx/LMTX and Anavex/2-73 have an interesting relationship.
LMTX is basically just methylene blue. One of Anavex's most advanced patent applications (14/205637) covers a combination therapy of Anavex 2-73 + methylene blue for the treatment of cancer and neuropathic pain.
If LMTX and 2-73 prove to be independently successful for the treatment of Alzheimer's, perhaps we may see the Anavex 2-73 + methylene blue combo therapy expand to cover the treatment of Alzheimer's as well. Who knows - maybe we will even see Anavex PLUS+ (2-73 + donepezil + methylene blue).
2-73 could turn into quite the pipeline all by itself."
Methylene Blue has apparently been around for a long time. Perhaps Orveko may be able to comment about whether Methylene Blue or its molecule by itself is perhaps not subject to patent, and the significance of the patent that Anavex has on the combination of Methylene Blue and AVXL 2-73 for cancer and neuropathic pain , the patent that Anavex has on AVXL 2-73, and whether Anavex needs a patent on the combination of Methylene Blue and AVXL 2-73 for the treatment of AD?
What Reyeton says is particularly relevant. Other companies are working on new treatments for AD as opposed to the drugs on the market that do not work. Anavex is, among other things, focusing on protecting its market, lawfully of course, so that it will be able to recoup its efforts and investment over all of the years it has spent to develop its drugs. This is in no way a criticism of Anavex. What I mean to say is that many other companies are attempting to develop drugs along the same lines as Anavex's drug discoveries. The way to protect Anavex's market lawfully is through filing patents. Patent monopolies are lawful and for good reason.
Yes, what you get from the MF or anyone else for free is worth what you pay for it, and it may even be dangerous to your financial well being. MF constantly assigns staff to write these pieces for its bait and switch strategy -- give the reader something for nothing and lure them into their system by switching at the very end to "now if you want to get rich by getting Tom's and David's hot stock tips click here."
I think the attorneys that sued Anavex- Missling for fraud in attempting to drive the price higher (which prices collapsed later allegedly due the news releases being false) would have a conflict in also suing shorts to recover damages for driving the price down. If the shorts issued false articles to drive the price down,
that conflicts with the existing suit against Anavex.
Yes, and it may be true that references to the piano playing, etc., cannot be used to support another use for 2-73 for Rhett Syndrome; however, the safety data and other data about 2-73 in humans in the AD study can be used for the application for Rhett, I believe.
My understanding is that all information between Anavex and the FDA is confidential, but nothing prohibits Anavex from referencing or cross referencing to the FDA all information about its drug or drugs in support of any drug application for the uses of that drug.
Yes. The company cannot promote it off label, but physicians may prescribe it off label once the FDA approves use of 2-73 for any disease. You can bet Alzheimer's patients and/or their families will be requesting it, and what doctor would not prescribe it off label when nothing else works?
Yes, that -- what you quote -- is key. AF types will say orphan designation is meaningless, which by itself is not true, but this situation is very different. 2-73 safety has been proven! Although not the purpose of the early trials for AD, indications are that the AZ patients in the 2-73 AD trials are for some reason functioning and doing well for now. Plus, the FDA has information about 2-73 that none of us or the AF cartel has. Would the FDA grant orphan status and fast track testing of 2-73 if they thought it was just being promoted as the snake oil of this century as AF implies in his "little tweets?"
Proceed with your meaningless tweets AF! Tweet, tweet tweet!
Hey, now that sounds like a great way to spend an afternoon! Good luck.
AF did not intend the tweet to positive, my friend. He is mocking. He is an inverterate AH.
Our Federal Government, still lists salmon, almonds and avocados as unhealthy foods, but cereals like Frosted Flakes are listed as healthy foods for us to eat. The FDA, I suppose, will "protect us" from Anavex 2-73 I am sure. It would be unethical for us to resume even a semblance of leading a normal life by doing so. Thank God for Australia, Japan, or any other countries that may not exert the same "protection" or "ethics". We need to insist that the FDA and other government agencies join the present century. I can decide for myself whether to eat Frosted Flakes, salmon, olives or avocados.
Right!
Anavex 2-73
It's just the thing for me
I don't know how life will be
If that FDA keeps Anavex 2-73
Away, away from me
Oh Lord want you make them
Give Anavex 2-73 to me!
We have been down the last 5 trading days, but look at the 3 month chart. That trend seems to be upward and intact. The share price during the last five days has been able to remain in the $5 area despite the negative attacks.
Yes, a good article. The article says: "It seems more are rooting for the company to fail than succeed and we find this astonishing."
It has been difficult for AVXL, but it has been succeeding despite all of the pessimism. This makes me even more encouraged.
"The pessimist sees difficulty in every opportunity. The optimist sees the opportunity in every difficulty." Winston Churchill
I see opportunity.
The truth is that Orphan Designation may or may not prove to be significant. I have no problem with the PR, because I read the announcement with the understanding that the designation could be significant for a number of reasons. It may be that the designation will, down the road, turn out to be meaningless. However, I believe it is premature to say that the designation has no meaning although it may prove to be meaningless.
If we longs are right, we should exercise restraint and sit tight. AVXL stock price remains at a level that, if we are correct, will eventually show a great profit. Disregarding the swings in trying to jump in and out will likely prove to be fatal because nobody can catch all the fluctuations.
I say this from personal experience. Some years ago, I purchased REGN at $20 per share. It eventually went to $70, and I sold because a Motley Fool article said it was over bought/over priced. After I sold, the stock price of REGN shot up dramatically to a few hundred dollars per share. I lost the big move, because I did not sit tight. REGN closed Friday at around $404 per share. I sold REGN thinking I would get back in at a price much less than my $70 per share. That never happened, and I turned out to be just another Fool.
I have been doing AVXL DD for about two years. I have bought and sold a few shares, but all the while I have been accumulating shares to increase my overall position. I think I am right about AVXL having great potential.
Most great investments begin in discomfort. The things most people feel good about – investments where the underlying premise is widely accepted are unlikely to be available at bargain prices. Rather, bargains are usually found among things that are controversial, that people are pessimistic about, and that maybe have performed badly for a long while (look at the long term chart for AVXL - AVXL's stock performed badly for a long time). Buying AVXL stock has at times been uncomfortable. Sometimes it has been painful owing AVXL stock. It is NEVER easy to do things that entail discomfort, but being uncomfortable comes with the territory when investing in new ideas.
Innovative ideas like this, AVXL's new class of drugs, have to be lonely. By definition, non-consensus ideas that are popular and widely held or obvious are an oxymoron. Thus, such new ideas are oxymoron and uncomfortable. Non-conformists don’t enjoy the warmth that comes with being at the center of the herd. Unconventional ideas often appear imprudent because what AVXL is doing is something that is NOT "what everyone does.” You will never make any serious money doing what everyone else does. Most of the other drug companies, big pharma, are doing something else -- something else that's not working.
This is really the bottom-line: whether you dare to be different. Do you dare to look wrong. Any new, innovative, revolutionary idea has to go through the stage of looking wrong because you are doing something that no one else is doing.
As an investor, don't worry about what the herd thinks or is doing. Do diversify your investments (don't invest money here that you cannot afford to lose). However, do not believe that you should never buy something because you may look bad. If you worry about temporarily looking bad you must understand that it will keep you from buying enough of something that works for it to make much of a difference for the better.
I am long, I believe what most longs on this board believe -- that we are right about AVXL and that it will eventually be successful in a big way. However, it will take time. In the meantime, have patience. Ignore the "noise". The Fool is simply "noise". I believe I am right. So, I will sit tight!
Opphan Drug approval for a drug compound is certainly not a negative. Furthermore, it may result in a confirmation of safety, and may help lead to the discovery of other effective uses of the compound. However, I do agree that AVXL 2-73 is the molecule for the time being.
APDN price crossed the long term trend line, and it looks very strong technically at least. We shall see.
Karen: Thank you.
Chaikin rates AVXL bearish (no surprise), although that does not mean that the stock cannot turn bullish quickly -- especially since it's a startup biotech awaiting an important clinical trial report. Significantly, the Chaikin power gauge report states that insiders are buying. If true, the latter is confirmation of good results that may be reported. The question is when? I keep am telling myself (I talk to myself a lot) that three things are important for my long position at this juncture: 1. Patience 2. Patience, and 3. More patience.
Rett syndrome is a rare genetic postnatal neurological disorder of the grey matter of the brain that almost exclusively affects females but has also been found in male patients. The clinical features include small hands and feet and a deceleration of the rate of head growth (including microcephaly in some). (Paraphrased from Wikipedia).
Onset occurs between 6 and 18 months of age. It is a horrible disease. There is no cure.
Three reasons for Anavex to move on Rhett syndrome are: 1. Funding is more likely to be available. 2. It is a rare disease (fast track). 3. There is no cure (fast track).
I believe that fast track development is virtually guaranteed.
It is interesting to note microcephaly is a feature in some victims. With the Zika virus rapidly developing, microcephaly will be on the increase. Query: If AVXL-273 works to treat Rhett syndrome, will it work to treat microcephaly?
Excellent! If you are right, sit tight! That's the only way to make big money. Investors that can be both right and sit tight or uncommon. It is a difficult thing to do.
The reason is that an investor may see clearly and yet become impatient or doubtful when the stock takes its time about doing what we surmise it should do. ''The market does not beat them. They beat themselves, because though they have the brains they cannot sit tight..…". Reminisces of a Stock Operator, p.57
Innovation is where we may make major money, but it takes time. Major breakthroughs are going to be taking place in cancer, heart disease, Alzheimer’s, ALS, diabetes, multiple sclerosis, Parkinson's and other diseases. Picking the right companies can produce impressive returns even in a difficult overall market environment.
This was written generally about holding stocks in bull markets or shorting stocks in bear markets, but I think it applies in special situations in the biotech area (forgive me for any typos I may miss):
Page 57:. Reminisces of a Stock operator
"After spending many years in Wall Street and after making and losing millions of dollars I want to tell you this: It never was my thinking that made big money for me. It always was my sitting. My sitting tight! You always find lots of early bulls for markets generally bears and bear markets. I've known many men who were right at exactly the right time, and began buying or selling stocks when prices were at the very level which should show the greatest profit. And their experience invariably matched mine – that is, they made no real money out of it. Men who can be both right and sit tight or uncommon. I found it was the hardest things to learn.
The reason is that a man may see straight clearly and yet become impatient or doubtful when the market takes its time about doing as he figured it must do. The market does not beat them. They beat themselves, because though they have the brains they cannot sit tight..…
........One of the most helpful things that anybody can learn is to give up tryinvg to catch the last eight – the first."
AVXL has excellent representation in the securities law suit. The law suit is much ado about nothing. AVXL is in good hands: David H. Kistenbroker is Co-Leader of the white collar and securities litigation practice of Dechert LLP and managing partner of the firm’s Chicago office. ... Mr. Kistenbroker frequently writes and lectures on the topics of securities litigation, directors’ and officers ...
If you are speaking about a Pro Hac Vice filing, it really does not mean much except it is a motion by an attorney requesting permission from the Court to enter an appearance and represent a client in this particular federal court although the attorney in question is not admitted to practice law in that specific jurisdiction. Say for example, the attorney is admitted in California but not NY, the attorney must file such a motion in the NY court to gain permission to represent a client in the NY court.
I think that is likely to occur -- that the patent will eventually be approved.
Josh: It means that this is good news.